JP2021512947A - Ｔｔｐの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法 - Google Patents

Ｔｔｐの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法 Download PDF

Info

Publication number
JP2021512947A
JP2021512947A JP2020563820A JP2020563820A JP2021512947A JP 2021512947 A JP2021512947 A JP 2021512947A JP 2020563820 A JP2020563820 A JP 2020563820A JP 2020563820 A JP2020563820 A JP 2020563820A JP 2021512947 A JP2021512947 A JP 2021512947A
Authority
JP
Japan
Prior art keywords
polypeptide
ttp
vwf
days
episode
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020563820A
Other languages
English (en)
Japanese (ja)
Inventor
フィリップ・カレヴェート
ヒルデ・デ・ヴィンテル
Original Assignee
アブリンクス・エヌ・フェー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブリンクス・エヌ・フェー filed Critical アブリンクス・エヌ・フェー
Publication of JP2021512947A publication Critical patent/JP2021512947A/ja
Priority to JP2023172414A priority Critical patent/JP2024001135A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020563820A 2018-02-06 2019-02-06 Ｔｔｐの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法 Pending JP2021512947A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023172414A JP2024001135A (ja) 2018-02-06 2023-10-04 Ｔｔｐの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862627082P 2018-02-06 2018-02-06
US62/627,082 2018-02-06
US201862662381P 2018-04-25 2018-04-25
US62/662,381 2018-04-25
PCT/EP2019/052929 WO2019154867A1 (en) 2018-02-06 2019-02-06 Methods of treating initial episode of ttp with immunoglobulin single variable domains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023172414A Division JP2024001135A (ja) 2018-02-06 2023-10-04 Ｔｔｐの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法

Publications (1)

Publication Number Publication Date
JP2021512947A true JP2021512947A (ja) 2021-05-20

Family

ID=65440943

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020563820A Pending JP2021512947A (ja) 2018-02-06 2019-02-06 Ｔｔｐの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法
JP2023172414A Pending JP2024001135A (ja) 2018-02-06 2023-10-04 Ｔｔｐの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023172414A Pending JP2024001135A (ja) 2018-02-06 2023-10-04 Ｔｔｐの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法

Country Status (15)

Country Link
US (1) US11999797B2 (https=)
EP (1) EP3749696A1 (https=)
JP (2) JP2021512947A (https=)
KR (1) KR102929403B1 (https=)
CN (1) CN111670202A (https=)
AU (1) AU2019217584B2 (https=)
BR (1) BR112020015991A2 (https=)
CA (1) CA3089211A1 (https=)
IL (1) IL276200B2 (https=)
MX (1) MX2020008294A (https=)
MY (1) MY204220A (https=)
SG (1) SG11202006902QA (https=)
TW (1) TWI889647B (https=)
WO (1) WO2019154867A1 (https=)
ZA (1) ZA202004370B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201805064SA (en) * 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519762A (ja) * 2014-06-16 2017-07-20 アブリンクス エン．ヴェー． 免疫グロブリン単一可変ドメインでｔｔｐを処置する方法、およびその使用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CA2361678A1 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
IL147920A0 (en) 1999-08-02 2002-08-14 Keygene Nv Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
BRPI0315666B8 (pt) 2002-10-23 2021-05-25 Ludwig Inst For Cancer Res Ltd dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
NZ576284A (en) 2003-01-10 2010-07-30 Ablynx Nv Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
EP1656128A4 (en) 2003-08-12 2007-02-28 William M Yarbrough SINGLE ACNE TREATMENT AND METHOD OF USE
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006074947A2 (en) 2005-01-14 2006-07-20 Ablynx N.V. METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2121757A2 (en) 2007-02-21 2009-11-25 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
EP2252303A2 (en) 2008-03-21 2010-11-24 Ablynx NV Von willebrand factor specific binders and methods of use therefor
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
WO2010091396A2 (en) * 2009-02-09 2010-08-12 Archemix Corp. Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics
US20120321640A1 (en) 2009-12-01 2012-12-20 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
DK3412305T3 (da) 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519762A (ja) * 2014-06-16 2017-07-20 アブリンクス エン．ヴェー． 免疫グロブリン単一可変ドメインでｔｔｐを処置する方法、およびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. Vol.130, Suppl 1: LBA-1, JPN6023002218, 2017, pages 1 - 5, ISSN: 0005188734 *
N ENGL J MED, vol. 374, JPN6023002220, 2016, pages 511 - 522, ISSN: 0005188735 *

Also Published As

Publication number Publication date
ZA202004370B (en) 2024-08-28
US20210221912A1 (en) 2021-07-22
KR20200118444A (ko) 2020-10-15
BR112020015991A2 (pt) 2020-12-15
TW201945030A (zh) 2019-12-01
WO2019154867A1 (en) 2019-08-15
RU2020129228A (ru) 2022-03-09
CA3089211A1 (en) 2019-08-15
MY204220A (en) 2024-08-16
CN111670202A (zh) 2020-09-15
SG11202006902QA (en) 2020-08-28
IL276200B1 (en) 2024-09-01
MX2020008294A (es) 2020-11-18
TWI889647B (zh) 2025-07-11
JP2024001135A (ja) 2024-01-09
US11999797B2 (en) 2024-06-04
IL276200B2 (en) 2025-01-01
EP3749696A1 (en) 2020-12-16
KR102929403B1 (ko) 2026-02-24
AU2019217584B2 (en) 2025-08-14
IL276200A (en) 2020-09-30
AU2019217584A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
JP7105260B2 (ja) 免疫グロブリン単一可変ドメインでｔｔｐを処置する方法、およびその使用
JP2024001135A (ja) Ｔｔｐの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法
RU2794143C2 (ru) Способы лечения первоначального эпизода ttp с помощью одиночных вариабельных доменов иммуноглобулинов
RU2807602C2 (ru) Способы лечения ттп иммуноглобулиновыми одиночными вариабельными доменами и их применение
HK1256731B (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1255930B (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1255930A1 (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1256730B (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1258508B (en) Methods of treating ttp with immunoglobulin single variable domains and uses thereof
HK1236434B (en) Immunoglobulin single variable domains for use in treating ttp

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230419

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231004

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231012

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231110